Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Total Current Liabilities (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Total Current Liabilities for 4 consecutive years, with $20.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities rose 27.36% to $20.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $20.7 million, a 27.36% increase, with the full-year FY2024 number at $16.2 million, up 44.6% from a year prior.
  • Total Current Liabilities was $20.7 million for Q3 2025 at Orchestra BioMed Holdings, up from $17.1 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $21.5 million in Q3 2023 to a low of $306538.0 in Q1 2022.
  • A 4-year average of $12.6 million and a median of $14.5 million in 2024 define the central range for Total Current Liabilities.
  • Biggest YoY gain for Total Current Liabilities was 3833.28% in 2023; the steepest drop was 39.63% in 2023.
  • Orchestra BioMed Holdings' Total Current Liabilities stood at $18.6 million in 2022, then plummeted by 39.63% to $11.2 million in 2023, then skyrocketed by 44.6% to $16.2 million in 2024, then rose by 27.44% to $20.7 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Total Current Liabilities are $20.7 million (Q3 2025), $17.1 million (Q2 2025), and $15.5 million (Q1 2025).